CURE GABA-A | Grann Pharmaceuticals: mRNA Protein Replacement for GABAAR Disorders
π
Friday, September 26th 2025
π 1:00 PM PST | 4:00 PM EST
Online Event (Zoom link provided upon registration)
π¨ STOP WHAT YOUβRE DOING π¨
This is the moment everything weβve worked for comes down to. We started CURE GABA-A with one mission: to get pre clinical data for treatments relating to GABAAR disorders as quickly and safely as possible. And now, we are finally at the beginning.
Grann Pharmaceuticals has developed an mRNA-based protein replacement therapy for GABRA1 and GABRG2 variants. This therapy is already produced and ready for preclinical testing. With the right support, we can bring it to the FDA and into clinical trials by the end of 2026.
But science alone isnβt enough. We need the community to band together now, fundraising, donating, and spreading the word, to make this therapy a reality for children and families.
Join us for a live Q&A with Tommy Temple, CEO of Grann Pharmaceuticals, as he explains:
π Together we can move from hope to treatment.
ποΈ Free β Registration required.
Donations encouraged: https://www.facebook.com/donate/4300256346872932/
or GoFundMe: https://www.gofundme.com/f/lifesaving-gene-therapy-drug
β¨ Every donation moves us closer to the first-ever GABAAR clinical trial.
β¨ Every fundraiser brings hope to families waiting for answers.
π Register now, join the movement, and help us make history.